Invest in

Biotech Breakthroughs

3.4%
0.9%
0.0%

Feeling Better About Biotech

The next big cure for a complex, scary disease is unlikely to come from old-school pharma. It’s likely coming from biotech. Scientists, investors, and patients are all banking on the $93 billion biotech industry.[1] It’s outpaced Big Pharma in finding treatments for cancer, AIDS, multiple sclerosis, and other diseases. The FDA approved 43 drugs in 2012, a 20% jump from the previous year.[4] Big Pharma has responded by snapping up promising biotech and smaller pharmaceutical companies, at lofty valuations, with premiums for several public companies in excess of 50%.[2] In fact, 2013 was a big year for the biotech industry, with $29B in M&A deals through the 1st half of 2013.[3] This motif includes only biotech companies with at least two years of cash flow to help screen out companies at greater risk of losing money. See more
3.4%
0.9%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Biotech Breakthroughs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
35.6% Cancer 7.0%
18.4% Amgen Inc. AMGN 1.2%
15.2% Celgene Corporation CELG 12.2%
1.0% SciClone Pharmaceuticals Inc. SCLN 25.9%
1.0% Seattle Genetics Inc. SGEN 70.5%
17.9% Other Diseases 1.8%
6.2% Regeneron Pharmaceuticals Inc. REGN 8.1%
4.8% Alexion Pharmaceuticals Inc. ALXN 26.4%
4.7% Vertex Pharmaceuticals Incorporated VRTX 35.1%
1.6% United Therapeutics Corporation UTHR 3.0%
0.6% Acorda Therapeutics Inc. ACOR 46.3%
16.7% Research & Diagnostics 15.2%
7.3% Quintiles IMS Holdings Inc. Q 18.4%
3.6% Illumina Inc. ILMN 22.2%
3.0% Charles River Laboratories International Inc. CRL 10.5%
1.8% Bio-Techne Corp TECH 10.6%
1.1% Luminex Corporation LMNX 8.8%
16.3% Autoimmune Disorders 12.0%
8.4% Biogen Inc. BIIB 2.6%
3.4% Incyte Corporation INCY 58.7%
3.3% BioMarin Pharmaceutical Inc. BMRN 1.9%
1.1% Rigel Pharmaceuticals Inc. RIGL 21.7%
13.5% Infectious Diseases 32.5%
12.6% Gilead Sciences Inc. GILD 32.9%
1.0% Emergent Biosolutions Inc. EBS 26.2%

Quotes delayed 15 mins. Currently Apr 24, 2017 9:12:01 AM. Fields are marked with -- when data is unavailable.